Skip to content
Evotec
-
Evotec inks AI drug discovery deal with Odyssey Therapeutics for inflammatory diseases
The companies will combine Evotec’s screening technologies, compound libraries and AI-enabled discovery platform with Odyssey’s expertise in the biology of autoimmune and inflammatory diseases.
-
Niagen Bioscience selects Evotec to advance Ataxia Telangiectasia Drug Candidate NB4168
The companies will work together to generate pharmacological and bioanalytical data needed to advance NB4168 toward clinical development.